Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 12/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MTOR | P42345 | 7/20 | 0.44 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.40 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.39 |
| ▸ | SYK | P43405 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12166240 | 0.85 | PIK3CA (0.51) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL13298749 | 0.85 | PIK3CA (0.48) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL13059936 | 0.85 | PIK3CA (0.50) | PIK3CAPIK3R1MTORPIK3CDPIK3CB | |
| SCHEMBL1864522 | 0.85 | PIK3CA (0.56) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL1862571 | 0.85 | SMN1; SMN2 (0.47) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL26079024 | 0.85 | PIK3CA (0.50) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL1864899 | 0.85 | PIK3CA (0.51) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL1621374 | 0.84 | SMN1; SMN2 (0.49) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL2817644 | 0.83 | PIK3CA (0.51) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD | |
| SCHEMBL1862202 | 0.83 | SMN1; SMN2 (0.51) | PIK3CAPIK3R1SMN1; SMN2MTORPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112920199-A | Piperazinone substituent or derivative thereof, and preparation method, application and pharmaceutical composition thereof | 四川大学 | 2021-06-08 | — | — | CN | claimed |
| EP-2214675-B1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH INC (US) | 2013-11-20 | — | — | EP | claimed |
| US-8354528-B2 | Process for making thienopyrimidine compounds | GENENTECH, INC. (US) | 2013-01-15 | — | — | US | claimed |
| CN-101909631-B | Process for making thienopyrimidine compounds | GENENTECH INC | 2012-09-12 | — | — | CN | claimed |
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENETECH, INC | 2010-11-18 | — | — | US | claimed |
| EP-2214675-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | Genentech, Inc. (US) | 2010-08-11 | — | — | EP | claimed |
| US-7591999-B2 | Powdery preparation for nasal administration | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-09-22 | — | — | US | claimed |
| WO-2009055730-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | GENENTECH, INC. (US) | 2009-04-30 | — | — | WO | claimed |
| US-20060204448-A1 | Powdery preparation for nasal administration | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-09-14 | — | — | US | claimed |
| EP-4694893-A1 | NOVEL INHIBITORS OF PIKFYVE AND METHODS USING SAME | TME Therapeutics LLC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | CURIS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | CURIS INC (US) | 2025-07-17 | — | — | US | disclosed |
| EP-3849554-B1 | COMBINATION THERAPY WITH A PHOSPHOINOSITIDE 3-KINASE INHIBITOR WITH A ZINC BINDING MOIETY | CURIS INC (US) | 2025-01-29 | — | — | EP | disclosed |
| CN-119161359-A | Novel 4-morpholinyl thieno [3,2-d ] pyrimidine compound containing acrylamide structure and application thereof | 辽宁大学 | 2024-12-20 | — | — | CN | disclosed |
| US-20060204448-A1 | Powdery preparation for nasal administration | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1673087-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2006046031-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046040-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006046035-A1 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| WO-2005032484-A2 | ALKOXY SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292468-A1 | PROCESS FOR MAKING THIENOPYRIMIDINE COMPOUNDS | PIK3CA, PIK3CD, PIK3CB | PIK3CA 1/4885PIK3R1 16/4885SMN1; SMN2 3575/4885 |
| US-20250230169-A1 | Phosphoinositide 3-Kinase Inhibitors with a Zinc Binding Moiety | BAZ2A, BAZ2B, PI4KB | PIK3CA 57/4885PIK3R1 106/4885SMN1; SMN2 4184/4885 |
| US-12403142-B2 | Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety | PDPK1, PDCD1, PDCD1LG2 | PIK3CA 30/4885PIK3R1 52/4885SMN1; SMN2 3899/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.